Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants

Moresco, Luca; Sjögren, Alice; Marques, Keri A; Soll, Roger; Bruschettini, Matteo

doi:10.1002/14651858.cd015462.pub2

Cochrane Database of Systematic Reviews

2023

DOI: 10.1002/14651858.cd015462.pub2

|View full text |Cite

Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants

Luca Moresco,

Alice Sjögren,

Keri A Marques

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2025

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Methylxanthine for preventing morbidity and mortality in preterm infants: a network meta-analysis

Kinoshita,

Del Giovane,

Mitra

et al. 2023

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Methylxanthine for preventing morbidity and mortality in preterm infants: a network meta-analysis

Kinoshita,

Del Giovane,

Mitra

et al. 2023

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Strategies for cessation of caffeine administration in preterm infants

Urru,

Geist,

Carlinger

et al. 2024

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

BPD: Latest Strategies of Prevention and Treatment

Durlak,

Thébaud

2024

Neonatology

View full text Add to dashboard Cite

Background: Bronchopulmonary dysplasia (BPD) is the most common long-term complication of extreme preterm birth. It is associated with lifelong multisystemic consequences. Advances in neonatal care have not reduced the incidence of BPD and no new breakthrough therapy has been successfully translated into the clinic in recent decades. Summary: Current evidence demonstrates benefit of new modalities of first-line noninvasive positive pressure ventilation, selected strategies of postnatal corticosteroid administration, alternative surfactant delivery methods, and caffeine. Promising emerging therapies that are being translated from bench to bedside include mesenchymal stromal cells (MSCs), insulin-like growth factor 1/binding protein-3 (IGF-1/IGFBP-3), and interleukin 1 receptor (IL-1R) antagonist (anakinra). Strong preclinical data support efficacy of MSCs in attenuating neonatal lung injury. Early-phase clinical trials have already demonstrated safety and feasibility in preterm infants. Phase II studies that aimed at demonstrating efficacy are currently underway. Both IGF-1/IGFBP-3 and IL-1R antagonist present with biological plausibility and animal data of efficacy. Phase I/II clinical trials are currently recruiting patients. Key Messages: Early noninvasive respiratory support, late systemic dexamethasone, less invasive surfactant administration, and caffeine are proven strategies in reducing the risk of BPD. Potentially disruptive therapies – MSCs, IGF-1/IGFBP-3, and anakinra – are being advanced to clinical trials and their efficacy in remains to be demonstrated. Continued research efforts are needed in the growing population of extremely preterm infants at risk of developing BPD.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants

Cited by 4 publications

References 83 publications

Methylxanthine for preventing morbidity and mortality in preterm infants: a network meta-analysis

Methylxanthine for preventing morbidity and mortality in preterm infants: a network meta-analysis

Strategies for cessation of caffeine administration in preterm infants

BPD: Latest Strategies of Prevention and Treatment

Contact Info

Product

Resources

About